PDEPT: polymer-directed enzyme prodrug therapy
暂无分享,去创建一个
R. Duncan | T. Connors | R Satchi | T A Connors | R Duncan | R. Satchi | Ruth Duncan
[1] Duncan,et al. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? , 1999, Pharmaceutical science & technology today.
[2] C. Conover,et al. Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. , 1998, Anti-cancer drug design.
[3] Young,et al. Gene directed enzyme prodrug therapy for cancer. , 1997, Advanced drug delivery reviews.
[4] C. Springer,et al. Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs , 1996 .
[5] A. Photiou,et al. Antibody-directed enzyme prodrug therapy (ADEPT). , 1996, International journal of oncology.
[6] T. A. Connors. Is there a future for cancer chemotherapy? The Michel Clavel Lecture. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Connors Ta. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995 .
[8] S. Sharma,et al. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] K. Ulbrich,et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. , 1994, British Journal of Cancer.
[10] H. Svensson,et al. Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates. , 1994, Bioconjugate chemistry.
[11] R. Duncan,et al. Drug-polymer conjugates: potential for improved chemotherapy. , 1992, Anti-cancer drugs.
[12] C. Springer,et al. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. , 1991, European journal of cancer.
[13] S. Skinner,et al. Microvascular architecture of experimental colon tumors in the rat. , 1990, Cancer research.
[14] V. Šubr,et al. Immunogenicity of Protein-N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates in A/J and B10 Mice , 1990 .
[15] K. Ulbrich,et al. The pharmacokinetics of polymer-bound adriamycin. , 1990, Biochemical pharmacology.
[16] K. Ulbrich,et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. , 1989, Biomaterials.
[17] H. Dvorak,et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.
[18] K. D. Bagshawe,et al. Antibody directed enzymes revive anti-cancer prodrugs concept. , 1987, British Journal of Cancer.
[19] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[20] M. Keating,et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. , 1986, Drug metabolism and disposition: the biological fate of chemicals.
[21] N. Bleehen,et al. Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). , 1985, British Journal of Cancer.
[22] J. Kopeček,et al. Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes† , 1983 .
[23] Y. Ashihara,et al. Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum. , 1978, Biochemical and biophysical research communications.
[24] F M Muggia,et al. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] L. Murray,et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] D. Brewster,et al. Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.
[27] N. J. McNally,et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.
[28] K. Ulbrich,et al. Polymeric conjugates of drugs and antibodies for site‐specific drug delivery , 1996 .
[29] T. A. Connors. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995, Gene therapy.
[30] Z. Ram,et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer research.
[31] C Delgado,et al. The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.
[32] G. Dreyer,et al. The Blood Volume of Mammals as Determined by Experiments upon Rabbits, Guinea-Pigs, and Mice; and Its Relationship to the Body Weight and to the Surface Area Expressed in a Formula , 1911 .